Marker Therapeutics (MRKR) Cash from Operations (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Cash from Operations of 1404192.0 for Q1 2026, up 74.47% year-over-year from 804842.08 in Q1 2025, and up 26.1% quarter-over-quarter from 1900106.0 in Q4 2025.
Marker Therapeutics (MRKR) Cash from Operations (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Cash from Operations for 17 consecutive years, with 1404192.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 74.47% year-over-year to 1404192.0; the TTM figure through Mar 2026 stood at 7918536.0 (up 37.02% YoY), while the FY2025 annual figure was 12014081.0, down 10.12% from the prior year.
- Cash from Operations rose to 1404192.0 in Q1 2026 per MRKR's latest filing, from 1900106.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 3731315.0 in Q4 2023 and bottomed at 12226062.0 in Q1 2022.
- Historically, Cash from Operations has averaged 3304862.29 across 5 years, with a median of 3567570.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 190.94% — and 2025, when it tumbled 328.47%.
- Marker Therapeutics' Cash from Operations stood at 4103184.0 in 2022, then soared by 190.94% to 3731315.0 in 2023, then slumped by 226.04% to 4703135.0 in 2024, then surged by 59.6% to 1900106.0 in 2025, then gained by 26.1% to 1404192.0 in 2026.
- Business Quant data shows MRKR's Cash from Operations at 1404192.0 in Q1 2026, 1900106.0 in Q4 2025, and 2735876.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | 3.73 Mn |
| Dec 31, 2023 | 3.73 Mn |